HVP COVID Report: Human Challenges to Accelerate SARS-CoV-2 Vaccine Development, No. 7 [May 11, 2020]   [open pdf - 0B]

This is the 7th issue of the Human Vaccines Project COVID [coronavirus disease] Report titled "Human Challenges to Accelerate SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] Vaccine Development" released on May 11, 2020. From the Document: "The SARS-CoV-2 virus is epidemic throughout the world, causing death and disruption on a catastrophic scale. Prevention of SARS-CoV-2 infections is therefore both a medical and societal priority. Vaccine development normally takes years from conception to licensure, and current estimates for SARS-CoV-2 vaccines require at least 12 to 18 months. There are over 70 vaccine candidates that will require clinical trials including placebo-controlled phase 3 efficacy trials. Large populations will be required, and it may be demanding to find places where the incidence is high enough given recommendations for social distancing. Such trials may take six months or more, with thousands of deaths occurring meanwhile. A strategy that could eliminate these difficulties is to use human challenge studies, in which well-informed volunteers are randomized to receive vaccine or placebo and then challenged or exposed to SARS-CoV-2 virus. Vaccines that demonstrate protection against the challenge could lead to rapid emergency use."

Human Vaccines Project
Retrieved From:
Human Vaccines Project: https://www.humanvaccinesproject.org/
Media Type:
Human Vaccines Project COVID Report (May 11, 2020), no.7
Help with citations